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Background: To compare the expression of receptivity markers in epithelial and stromal cells in the endometrium
of ovulatory women and infertile with hypothalamic pituitary dysfunction (HPD), untreated or treated with
clomiphene citrate (CC), or with recombinant follicle stimulating hormone (rFSH).
Methods: Twelve control ovulatory and 32 anovulatory women, 22 of whom received ovulation induction with CC
(n = 12) or rFSH (n = 10). Endometrial biopsies were obtained during the mid-secretory phase. Hormonal secretion
was measured by chemiluminescence immunoassay, endometrial dating and cellular expression and distribution of
receptivity proteins were evaluated by quantitative immunohistochemistry.
Results: CC or rFSH treatments, modified the expression of epithelial receptivity markers, such as Glycodelin A,
beta-catenin, CD166/ALCAM and IGF-1R, but not in stromal markers. Also, a change in their cell distribution was
observed.
Conclusions: Treatment of infertile women with HPD modified the expression and distribution of receptivity
markers in the mid-secretory phase of the endometrium in epithelial but not stromal cells, which can help to
explain changes in the receptivity of the endometrium during treatments and suggest an important role of these
cells in the receptivity window.
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Biochemical and morphological changes of the endo-
metrium during the secretory phase of the menstrual
cycle depend on complex cell signaling that leads to the
receptive state for embryo implantation. Consequently,
alterations of molecular or cellular interactions during
this period could have a negative impact on the success
of pregnancy [1,2].
Human endometrial receptivity refers to the ability of
the uterus to accept and develop a new embryo [3]. Several
studies have identified cell signaling pathways and specific* Correspondence: mcerbon85@yahoo.com.mx
1Unidad de Investigación en Reproducción Humana, Instituto Nacional de
Perinatología-Facultad de Química, Universidad Nacional Autónoma de
México, México, D.F., Mexico
Full list of author information is available at the end of the article
© 2015 Valdez-Morales et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.proteins involved in maturation, differentiation and func-
tionality of the endometrium [4,5]. Among proteins
expressed in luminal and glandular epithelia are: cadherins,
β-catenin, CD166/ALCAM, glycodelin A (GdA), leukemia
inhibitory factor (LIF), stem cell factor (SCF) and its re-
ceptor (c-Kit), epithelial growth factor (EGF), mucin-1
(MUC1), integrin αVβ3 and the insulin like growth fac-
tor (IGF) family [6–8]. Moreover, stromal protein
changes induced by cytokines and other immune medi-
ators, including interleukins (IL)-6 and 11, vascular
endothelial growth factor (VEGF), transforming growth
factor beta (TGF-β) family, CD34, CD31/PCAM-1,
CD44, matrix metalloproteinase proteins (MMP) and
the transcriptional regulators FOXO1, and HOXA10
[7,9] affect endometrial vascularization and decidualiza-
tion at varying degrees [10]. We and others have foundCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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or ovarian stimulation protocols develop molecular al-
terations of the endometrium [11–15].
Hypotalamic pituitary dysfunction (HPD) is character-
ized by lutheal phase deficiency, oligomenorrhoea and
anovulation with normal basal levels of serum FSH, LH
and estradiol [16,17]. The first election treatment in-
volves ovulation induction with clomiphene citrate (CC)
or gonadotrophins such as recombinant FSH (rFSH) to
obtain no more than two mature follicles. However the
side effects of the treatments include a decrease in endo-
metrial thickness and quality and also a reduction of the
number of glands per mm2 with smaller gland diameter
during secretory phase in CC-treated women, whereas
rFSH treatment increase the endometrial thickness
[18,19]. At molecular level, previously we reported an al-
teration of proliferation and cell death markers expression
as well as hormonal receptors in both treatments [15]. On
the other hand, it has also been shown that only 30 % of
all stimulated patients with CC or rFSH becomes pregnant
in spite of the efficient restitution of ovulation [15,18]. In
the present work we examined the molecular effects of
ovulation inducing agents (CC or rFSH), on endometrial
expression of stromal and epithelial receptivity markers
mentioned above and their cell distribution in the mid-
secretory endometrium of women with HPD.
Methods
Tissue collection
The study included women in reproductive age (26–31
years old) that either had normal ovulation or were an-
ovulatory and infertile. The latter category included
women with a diagnosis of HPD (according to the
WHO criteria, Type II infertility) [17] or oligomenor-
rhea. Women participating in this study were patients
at the National Medical Center “La Raza” of the Insti-
tuto Mexicano del Seguro Social from January, 2009, to
March, 2011. All patients gave their informed consent,
and the study was approved by the Institutional and
National Mexican Ethics Committees (trial registration
number: R-2014-3504-8) and performed in accordance
with international laws, according to Declaration of
Helsinki on procedures for the handling of human tissue.
Clinical treatment of the patients
Endometrial samples were obtained and divided into
four groups: a) control ovulatory women (n = 12); b)
anovulatory infertile patients treated with 100 mg of
CC per day from days 5 to 9 of the cycle (n = 12); c) an-
ovulatory infertile patients treated with a step-up
schedule of rFSH (n = 10); d) anovulatory infertile patients
with oligomenorrhea and without treatment (n = 10). The
patients without previous fertility treatments were ran-
domized for the administration ovarian stimulationtreatments. The rFSH treatment started on day 3 of the
menstrual cycle, with a dose of 50–75 IU per day. Follicular
growth was evaluated by ultrasonography on days 9–10,
and in accordance with this parameter doses were either
maintained or increased (in the latter case, up to 100–
150 IU of rFSH). Follicular growth was re-evaluated on day
11–12 of the cycle to determine if a follicular diameter of
18 mm had been attained. In such a case, doses were main-
tained. If not, the cycle was canceled.
Treated patients (groups’ b and c) were given 2 mg of
chlormadinone for 10 days. After menstruation, patients
were treated with CC or rFSH on the indicated days. All
women underwent an endometrial biopsy with Pipelle
cannula (CCD International, Paris, France) while they
were in the mid-secretory phase of the menstrual cycle
(LH + 7 days), which was determined based on the last
menstrual period and confirmed by histological dating.
All patients were monitored during treatments with
echographic endometrial pattern and thickness evalu-
ation, and of the growth and number of follicles. Hyster-
osalpingography was carried out for diagnosis and to
exclude other causes of infertility. Biopsies of untreated
infertile women with oligomenorrhea were obtained
randomly.
Endometrial histology and dating
Endometrial tissues were fixed in 3 % formalin and left
for 24 h at room temperature and we performed the
hematoxilin eosin staining as we reported before [15].
The sections were observed in a Nikon Eclipse E600
light microscope for analysis and photographs were
taken. The endometrial tissue was examined, dated and
analyzed histologically according to Noyes criteria [20].
Hormonal measurement
The hormonal serum levels of FSH, LH, estradiol, pro-
gesterone and prolactin (PRL) were determined in du-
plicate by chemiluminescence immunoassay (Inmulite
kit Diagnostic Products Corporation, Los Angeles, CA,
USA) before treatment (basal concentrations) and after
treatment on the day of the biopsy. The intra- and
inter-assay coefficients of variation were 5.4 and 6.6 %
for FSH, 6.5 and 10 % for LH, and 4.4 and 5.4 % for es-
tradiol, respectively.
Immunohistochemistry
As we reported previously [15], tissues were processed
and embedded in paraffin, and used for immunohisto-
chemistry assay to evaluate the expression of the epithe-
lial receptivity markers: GdA (Santa Cruz, CA, Dallas,
TX, USA; 1:100), LIF (R&D Systems, Minneapolis, MN,
USA; 1:100), C-Kit (Biocare, Concord, CA, USA; 1:250),
SCF (Biocare, Concord, CA, USA; 1:100), E-cadherin
(Dako, Carpinteria, CA, USA; 1:50), beta-catenin (Biocare,
Valdez-Morales et al. Reproductive Health  (2015) 12:45 Page 3 of 11Concord, CA, USA; 1:50) and IGF-1R (Biocare, Concord,
CA, USA; 1:100). To evaluate molecules related to endo-
metrial stromal decidualization, we used: ALCAM/CD166
(Abcam, San Francisco, CA, USA; 1:100), TGF-β (Santa
Cruz, CA, Dallas, TX, USA; 1:100), VEGF (Biocare, Con-
cord, CA, USA; 1:100), CD34 (Biocare, Concord, CA,
USA; 1:100), CD44 (Biocare, Concord, CA, USA; 1:100)
and CD31/PCAM-1 (Biocare, Concord, CA, USA; 1:100).
Tissues were analyzed in a Nikon Eclipse E600 microscope
and photographs from three different tissue areas were
taken randomly.
Image processing and analysis
The staining intensity (mean gray value) of immunoposi-
tive cells was evaluated with NIH Image J software. The
gray level was converted to a numerical value using a
scale of 0 (white) to 255 (black), as described previously
[21]. The immunopositive cell index was obtained by the
ratio of positive cells to total cells.
Statistical analysis
All data presented a Gaussian distribution, as shown by
analysis with D'Agostino & Pearson omnibus normality
test (Prisma 5.0 GraphPadSoftware, San Diego, CA,
USA). Immunohistochemistry data were analyzed by
using one-way ANOVA on each data set followed by the
post hoc Bonferroni test for multiple comparisons. The
Prism 5.0 program (Graph Pad Software, San Diego, CA,
USA) was used for calculating probability values. Results
were considered statistically significant with p < 0.05.
Results
1) Histological endometrial dating and hormonal levelsTable 1 Summary of clinical data from patients included in all grou
OP
No. of patients (n) 12
Age (years) 30.83 ± 3.27
Body mass index (kg/m2) 26.24 ± 2.70
Basal hormonal profile
PRL (ng/mL) 17.46 ± 2.44
E2 (pg/mL) 35.13 ± 1.85
LH (IU/L) 6.42 ± 1.16
FSH (IU/L) 7.27 ± 0.94
LH + 7 day hormonal profile
E2 (pg/mL) 26 ± 2.04
P4 (ng/mL) 12.01 ± 1.54
Histological dating (cycle day) 19 ± 0.42
Clinical data from the ovulatory patients (OP), untreated infertile (UI), clomiphene citrat
represents mean ± SE. Hormonal measurement at basal condition (day 3) and after treaIn concordance with our previous reported observa-
tions, in patients with HPD, we did not find histomor-
phological differences between normal and treated
women [15]. In addition, the histological dating of the
endometrium demonstrated similar values of endomet-
rial development in all groups. Moreover, evaluation of
hormonal levels of PRL, E2, P4, LH and FSH indicated
normal values in all groups (Table 1).
2) Differential expression of epithelial glycoproteins
Total expression of GdA showed a diminution in
treated patients in both CC and rFSH groups as com-
pared with control and untreated infertile groups (Fig. 1).
In contrast, no significant differences between groups
were found with LIF expression (Fig. 1).
Interestingly for GdA and all the studied markers a
broad cellular distribution was observed and due to their
complexity, these results were summarized in the Figs. 2
and 3. We found that GdA was expressed and distrib-
uted in the cytoplasm of glandular epithelial cells in
36 % of the ovulatory women. However, few if any stain-
ing was observed in the infertile groups. Nonetheless the
cellular distribution pattern of GdA was similar to ovula-
tory women in CC treated group while in rFSH group
the cellular distribution was similar with untreated infer-
tile women (Fig. 2a). LIF expression was distributed
mostly in the cytoplasm in all groups (Fig. 2b).
SCF and c-Kit immunostaining was observed in the
cytoplasm of the glandular epithelial cells and also in
the cell membrane of the stromal cells. However no
significant differences were observed between groups
(Additional file 1: Figure S1). The cellular distribution
variations of these markers are shown in Fig. 2c and d.ps
UI CC-treated rFSH-treated
10 12 10
31.32 ± 3.58 31 ± 4.39 30.46 ± 3.95
26.48 ± 2.91 26.74 ± 2.80 25.98 ± 2.70
13.78 ± 2.32 15.93 ± 2.82 12.75 ± 3.11
27.34 ± 3.12 46.61 ± 2.67 24.8 ± 2.28
4.98 ± 0.84 4.82 ± 1.07 5.80 ± 0.77
8.86 ± 1.16 5.79 ± 0.79 6.07 ± 0.64
31.05 ± 3.08 25.33 ± 2.16 48.51 ± 3.27
7.19 ± 1.98 20.87 ± 4.32 6.97 ± 1.14
19 ± 0.7 19 ± 0.44 17 ± 0.79
e (CC) and recombinant follicle stimulating hormone (rFSH) treated patients. Data
tments in LH + 7 day, as well as histological dating in all groups
Fig. 1 Endometrial expression of epithelial receptivity markers. Immunohistochemistry for GdA (a to g) and LIF (h to n). Positive staining was
observed in glandular epithelium (brown and arrows), which was counterstained with Hematoxylin (blue nuclei). (a) Human mid-secretory
endometrium and (h) human lung tissue was used as the positive control. (b and i) Human endometrium with no primary antibody served as
the negative control. (c and j) Ovulatory women. (d and k) untreated anovulatory infertile women. (e and l) CC-treated anovulatory infertile
women. (f andm) rFSH-treated women. (g) Optical density analysis of GdA in the glandular epithelium showed a significantly lower expression (*P < 0.05)
in CC- and rFSH-treated groups compared with ovulatory and untreated infertile women. (n) Optical density analysis for LIF showed no
significant differences between groups. GE = glandular epithelium; LE = luminal epithelium; S = stroma; OP = ovulatory women; CC = anovulatory
infertile patients treated with clomiphene citrate; rFSH = anovulatory infertile patients treated with the recombinant follicle stimulating hormone;
UI = anovulatory untreated patients. (Bar = 100 μm)
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molecules
The expression of E-cadherin and beta-catenin stain-
ing was detected at epithelial cytoplasmic/membrane
localization. Beta-catenin expression in the rFSH-treated
group was significantly lower than those observed in
ovulatory and CC-treated women. No significant differ-
ences were found in E-cadherin expression between
groups (Fig. 4).
Beta-catenin was mainly distributed in the basolateral
membrane in patients from the ovulatory group, and
similar distribution was observed in CC-treated women.
In contrast, no staining was predominantly observed inuntreated infertile and rFSH treated groups. In the case
of E-cadherin the cell distribution in ovulatory and CC-
treated patients was observed in the cytoplasm and
basolateral membrane, whereas the major distribution
was located only in the cytoplasm of untreated infertile
and rFSH-treated women (Fig. 2 e and f).
The expression of CD166/ALCAM was significantly
higher in the CC-treated group compared with ovulatory
and untreated infertile women (Fig. 5). CD166/ALCAM
distribution was observed in the cytoplasm and basolat-
eral membrane of glandular epithelial cells in CC- and
rFSH-treated patients, while in ovulatory women there
was a predominant distribution only in the basolateral
membrane. Moreover in untreated infertile women no
Fig. 2 Epithelial protein distribution analysis. Percentage of patients that expressed a different cell location of epithelial receptivity markers in
ovulatory patients (OP), untreated infertile (UI), CC treated and rFSH treated patients. (a) GdA, (b) LIF, (c) SCF, (d) c-Kit, (e) E-cadherin, (f) beta-catenin,
(g) CD166/ALCAM, and (h) IGF-1R
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tients a cytoplasmic staining was observed (Fig. 2g).
The expression of IGF-1R was also observed in the
cytoplasm/membrane in glandular epithelium, with a sig-
nificantly lower expression in the rFSH-treated group com-
pared with all other groups (Fig. 5). IGF-1R expression was
observed mainly in cytoplasm and basolateral membrane
in the ovulatory group, whereas in the other groups, cyto-
plasmic distribution was predominant (Fig. 2h).
4) No differences were detected in the expression of
endometrial stromal receptivity markers
To determine the expression of stromal receptivity
markers in mid-secretory endometrium, immunohisto-
chemistry assays were performed to evaluate the following
markers: VEGF, TGF-β, CD34, CD44 and CD31/PCAM-1.
Positive staining was observed for all markers preferen-
tially in the cytoplasm or membrane of the stromal cells,
with no significant differences between groups (Additional
file 2: Figure S2 and Additional file 3: Figure S3). Given
that no differences were observed between groups, we
summarized the quantification and cellular distribution of
these markers expression in Fig. 3.
To improve the understanding of the overall results of
this study in a physiological context, Fig. 6 summarizesthe main molecular endometrial alterations observed
after treatments with ovulation inducing agents and
their possible interactions.
Discussion
The medical treatment of first choice in HPD, to restore
the synchrony of ovarian follicular development is the
administration of ovulation-inducing agents, such as CC
or rFSH [22,23]. However, the effect of these treatments
on endometrial receptivity is under extensive investiga-
tion because of low rates of pregnancy observed after
treatments.
In a previous study, we demonstrated that CC and
rFSH treatments modified the expression of endometrial
functionality markers related with proliferation and cell
death in mid-secretory endometrium of HPD infertile
women [15], indicating that molecular evaluation of the
endometrial function is reliably to characterize the re-
ceptive phase [24–26].
In the present study the expression and distribution ana-
lysis of different glandular epithelial and stromal markers
of receptivity was performed in women with HPD and
after treatment with CC and rFSH. The molecules re-
ported here included epithelial GdA, LIF, SCF, C-Kit, E-
cadherin, beta-catenin, IGF-1R and CD166/ALCAM and
stromal VEGF, TGF-β, CD34, CD31/PCAM-1 and CD44,
Fig. 3 Stromal protein distribution analysis. Percentage of patients that expressed a different cell location of stromal receptivity markers in ovulatory
patients (OP), untreated infertile (UI), CC treated and rFSH treated patients. (a) VEGF, (b) TGF-β, (c) CD34, (d) CD44 and (e) CD31/PCAM-1
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ment in the epithelial function during the implantation
window such as epithelial adhesion, modulators of cell in-
vasion and growth factors as reported previously and their
role in first steps of decidualization process of stromal
cells.
It has been demonstrated that GdA, LIF, c-Kit and
SCF have a role in endometrial receptivity by modulat-
ing different physiological aspects of trophoblast inva-
sion, the feto-maternal defense and cell adhesion
[7,27,28]. Previous studies have reported a lower expres-
sion of GdA, progesterone receptor B and LIF in the
mid-secretory endometrium of infertile women [29].
Here, we found that GdA expression was significantly
lower in the glandular epithelial cells of infertile patients
treated with CC or rFSH compared with ovulatorywomen. Recent studies indicates that serum GdA/IGFBP-
1 ratio was higher in women who achieved pregnancy
compared to those who did not [30], and in the uterine
fluid of infertile women exhibited lower concentration of
GdA as compared with fertile women [31]. Our results
concur with this idea and suggest a detrimental effect of
CC or rFSH treatments on endometrial GdA expression.
It is well known that LIF plays a similar role to GdA
during implantation [32]. For example, in a previous study
it was demonstrated an interaction between embryo and
endometrium mediated by cell adhesion molecules. They
also indentified cytokine-cytokine receptor interactions
such as LIF, osteopontin, apolipoprotein D, fibroblast
growth factor 7 between other molecules [33]. However,
in our study, the endometrial expression of LIF was simi-
lar in all groups. This is in agreement with a previous
Fig. 4 Endometrial expression of epithelial receptivity markers. Immunohistochemistry for E-cadherin (a to g) and β-catenin (h to n). Positive staining
was observed in glandular epithelium and stroma (brown and arrows), which was counterstained with hematoxylin (blue nuclei). (a and h) Human
skin cancer tissue was used as the positive control. (b and i) Human endometrium with no primary antibody served as the negative control.
(c and j) Ovulatory women. (b and k) untreated anovulatory infertile women. (e and l) CC-treated anovulatory infertile women. (f and m) rFSH-treated
women. (g) Optical density analysis of E-cadherin in the glandular epithelium and stroma showed no significant differences in expression
between groups. (n) Optical density analysis for β-catenin showed a significantly lower expression (*P < 0.05) in the glandular epithelium
of the rFSH-treated group compared with ovulatory and CC-treated women. GE = glandular epithelium; LE = luminal epithelium; S = stroma;
OP = ovulatory women; CC = anovulatory infertile patients treated with clomiphene citrate; rFSH = anovulatory infertile patients treated with
the recombinant follicle stimulating hormone; UI = anovulatory untreated patients. (Bar = 100 μm)
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infertile women [34]. This indicates that LIF could play a
different role during this endometrial phase or is under
complex regulation, where CC or rFSH treatment did not
modify its expression.
During the implantation development, SCF exerts a
paracrine action by stimulating the trophoblast through
its c-Kit receptor. It was reported that SCF and c-Kit
were highly expressed in implanted human blastocysts
[35], suggesting a major role in this process. However, in
our study we did not find any significant differences in
endometrial SCF and c-Kit levels between groups. This
suggests, that SCF and c-Kit could not be involved in
the receptivity of the endometrial tissue.During the receptive phase, it has been demonstrated
that the endometrial expression of cell adhesion mole-
cules (CAMs) is sharply increased and contributes to
blastocyst attachment to uterine epithelium [36]. In the
present study a significantly lower expression of beta-
catenin was observed in the glandular epithelium in the
rFSH-treated group compared with ovulatory and CC-
treated women. Contrarily, no significant differences
were found in E-cadherin expression between groups.
These findings are important due to the fact that beta-
catenin has uterine function and participates in the regu-
lation of endometrial epithelial differentiation during
endometrial receptivity period [36,37]. Interestingly, a
recent in vitro study demonstrated a link between GdA
Fig. 5 Endometrial expression of epithelial receptivity markers. Immunohistochemistry for CD166/ALCAM (a to g) and IGF1-R (h to n). Positive
staining was observed in glandular epithelium (brown and arrows) and counterstained with Hematoxylin (blue nuclei). (a and h) Human tonsil tissue
was used as the positive control. (b and i) Human endometrium with no primary antibody served as the negative control. (c and j) Ovulatory women.
(d and k) untreated anovulatory infertile women. (e and l) CC-treated anovulatory infertile women. (f and m) rFSH-treated women. (g) Optical density
analysis of CD166/ALCAM in the glandular epithelium a significant higher expression (*P < 0.05) in CC-treated group compared with ovulatory
and untreated infertile women. (n) Optical density analysis for IGF1-R showed a significantly lower expression (*P < 0.05) in glandular epithelium of
rFSH-treated women compared with the other groups. GE = glandular epithelium; LE = luminal epithelium; S = stroma; OP = ovulatory women;
CC = anovulatory infertile patients treated with clomiphene citrate; rFSH = anovulatory infertile patients treated with the recombinant follicle
stimulating hormone; UI = anovulatory untreated patients. (Bar = 100 μm)
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hesion and formation of adherent junctions through
cytoskeletal reorganization in human endothelial cells
[38]. This correlates well with our findings of a signifi-
cant decrease in both GdA and beta-catenin expression
of rFSH treatment. However, further studies are needed
to determine the accurate mechanism of beta-catenin
role in endometrial function after rFSH treatment.
It has been demonstrated that ALCAM is expressed in
the endometrium and blastocysts during implantation.
Interestingly, we found a significantly higher expression
of this protein in the glandular epithelium of the CC-
treated group compared to ovulatory and untreated
infertile women. This finding is interesting because itis also known that CD166/ALCAM, activate an immuno-
logical response through the binding of T lymphocytes
with their CD6 receptor [39,40]. This suggests that CC
treatment could participate in the activation of endomet-
rial immunological response. However, more investigation
is required to further define the molecular mechanism of
CD166/ALCAM action.
It has been shown that IGF-1R, IGFBP-1 and its re-
ceptor may also play an important role during embryo
implantation by facilitating adhesion processes [41], and
extravillous trophoblast cell migration [42]. These fac-
tors are regulated during the secretory phase mainly by
progesterone [43]. In our study, IGF-1R expression in
glandular epithelial cells showed a significant diminution
Fig. 6 Summary of the main molecular changes and their interactions in infertile women with HPD, and differences between treatments: (a) CC
treated women and (b) rFSH treated women. Black arrows indicate the changes in expression of different markers. Dashed arrows indicate the
possible effects of these protein markers alterations
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groups, indicating that the lower expression observed may
have an influence in endometrial receptivity and with the
low rate of pregnancy. This idea is supported by a recent
work that demonstrated the over expression of miR-145
suppressed embryo epithelial communication by the
modulation of the expression of maternal IGF-1R in endo-
metrium which leads to implantation failure [44].
On the other hand, we did not observe differences in
the expression of stromal receptivity markers such as
VEGF, which promote decidualization and vascularization.
This molecule, together with CD31, CD34, CD44 regulates
vascular permeability, endothelial cell proliferation and
cell migration, which are involved in endometrial receptiv-
ity [45]. However, few or any studies have explored the
role of endometrial VEGF expression in infertile patients
under treatments [46,47]. Moreover, compared with
fertile women, patients with unexplained infertility have
lower levels of VEGF in the uterine fluid [48]. Contrarily,
in the present study no significant differences in VEGF
expression were found between groups. However, in
this regard, reports remains controversial and deserve
further investigation.The CD34, and CD31/PCAM-1 markers are trans-
membrane proteins related with vascular development
and adhesion in endothelial cells of the endometrial
stroma [49,50]. CD44 is expressed in the stroma, vessels
and glandular epithelium, and interacts with proteogly-
can, and also proposed to function as a mediator of
embryo-endometrial interaction [51]. However, no sig-
nificant differences between groups for CD44, CD34, or
CD31/PCAM-1 were detected.
It has been shown that TGF-β modulates maternal
immunotolerance during implantation. Besides, in vitro,
this cytokine regulates several molecules related to im-
plantation, such as VEGF, MMP-9, IGFBP-1 and LIF [52].
In our study, we did not find a significant difference in
TGF-β expression between groups this may be due that
TGF-β has a timing expression, or it is not related with
receptivity window during secretory phase. The results
related to cell marker distribution could be important
to explain the alteration at cellular level in endometrial
receptivity after stimulation treatments.
As we summarized in Fig. 6, the major findings of this
study were that in both ovarian stimulation treatments,
several markers expression were differentially modified
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served in the expression of cell adhesion, cell proliferation,
cell signaling and growth factors that could be related with
lower embryo implantation success. However, the accurate
role of each marker during implantation and pregnancy
should be well established and deserved more experimen-
tal research. Overall findings of this study could be rele-
vant for the interpretation of treatments molecular effects
in terms of clinical applications that allow to increase the
success of pregnancy.
Conclusion
The overall results indicated that treatments with ovula-
tion inducing agents modify the expression and distribu-
tion of epithelial but not of stromal receptivity markers in
the endometrium during the mid-secretory phase. Thus,
suggesting an important role of epithelial cells during
blastocyst implantation. The insights of this study may
contribute in understanding of molecular interactions and
endometrial function in the receptive phase, which should
be take in account to improve pregnancy rates after treat-
ments with ovulation inducing agents on infertile women.
Additional files
Additional file 1: Figure S1. Immunohistochemistry for SCF (A to G)
and c-Kit (H to N). Positive staining was observed in glandular epithelium
and stroma (brown and arrows), which was counterstained with Hematoxylin
(blue nuclei). (A and H) Human tonsil tissue was used as the positive control.
(B and I) Human endometrium with no primary antibody served as the
negative control. (C and J) Ovulatory women. (D and K) Untreated anovulatory
infertile women. (E and L) CC-treated anovulatory infertile women.
(F and M) rFSH-treated women. (G and N) Optical density analysis of
SCF and c-Kit showed no significant differences in the expression of
the markers between groups (*P<0.05). GE= glandular epithelium;
LE= luminal epithelium; S= stroma; OP= ovulatory women; CC= anovulatory
infertile patients treated with clomiphene citrate; rFSH= anovulatory
infertile patients treated with the recombinant follicle stimulating hormone;
UI= anovulatory untreated patients. (Bar=100 μm).
Additional file 2: Figure S2. Endometrial expression of stromal
receptivity markers. Immunohistochemistry for TGF-β (A to G) and VEGF
(H to N). Positive staining was observed in glandular epithelium and stroma
(brown and arrows), which was counterstained with Hematoxylin (blue
nuclei). (A and H) Human colon cancer tissue was used as the positive
control. (B and I) Human endometrium with no primary antibody
served as the negative control. (C and J) Ovulatory women. (D and K)
Untreated anovulatory infertile women. (E and L) CC-treated anovulatory
infertile women. (F and M) rFSH-treated women. (G and N) Optical density
analysis of TGF-β and VEGF showed no significant differences in the
expression of the markers between groups (*P<0.05). GE= glandular
epithelium; LE= luminal epithelium; S= stroma; OP= ovulatory women;
CC= anovulatory infertile patients treated with clomiphene citrate;
rFSH= anovulatory infertile patients treated with the recombinant follicle
stimulating hormone; UI= anovulatory untreated patients. (Bar=100 μm).
Additional file 3: Figure S3. Endometrial expression of stromal
receptivity markers. Immunohistochemistry for CD34 (A to G), CD44
(H to N) and (O to U) CD31/PCAM-1. Positive staining was observed in
glandular epithelium and stroma (brown and arrows), which was
counterstained with Hematoxylin (blue nuclei). (A, H and O) Human
tonsil tissue was used as the positive control. (B, I and P) Human
endometrium with no primary antibody served as the negative control.
(C, J and Q) Ovulatory women. (D, K and R) Untreated anovulatoryinfertile women. (E, L and S) CC-treated anovulatory infertile women.
(F, M and T) rFSH-treated women. (G, N and U) Optical density analysis
of CD34 and CD44 and CD31 showed no significant differences in the
expression of the markers between groups (*P<0.05). GE= glandular
epithelium; LE= luminal epithelium; S= stroma; OP= ovulatory women;
CC= anovulatory infertile patients treated with clomiphene citrate;
rFSH= anovulatory infertile patients treated with the recombinant follicle
stimulating hormone; UI= anovulatory untreated patients. (Bar=100 μm).
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